Background/Aims: Intrahepatic cholangiocarcinoma (ICC) is a complicated condition, with difficult diagnosis and poor prognosis. The expression and clinical significance of the farnesoid X receptor (FXR), an endogenous receptor of bile acids, in ICC is not well understood. Methods: Western blotting and immunochemical analyses were used to determine the levels of FXR in 4 cholangiocarcinoma cell lines, a human intrahepatic biliary epithelial cell line (HIBEpic) and 322 ICC specimens, respectively, while quantitative reverse transcription polymerase chain reaction was used to detect the mRNA levels of FXR in cholangiocarcinoma cell lines. We evaluated the prognostic value of FXR expression and its association with clinical parameters. We determined the biological significance of FXR in ICC cell lines by agonist-mediated activation and lentivirus-mediated silence. IL-6 expression was tested by an enzyme-linked immunosorbent assay and flow cytometry. In vitro, cell proliferation was examined by Cell Counting Kit-8, migration and invasion were examined by wound healing and transwell assays; in vivo, tumor migration and invasion were explored in NOD-SCID mice. Results: FXR was downregulated in ICC cell lines and clinical ICC specimens. Loss of FXR was markedly correlated with aggressive tumor phenotypes and poor prognosis in patients with ICC. Moreover, FXR expression also had significant prognostic value in carbohydrate antigen 19-9 (CA19-9) negative patients. The expression of FXR was negatively correlated with IL-6 levels in clinical ICC tissues. 
FXR Acts as a Metastasis

Introduction
Intrahepatic cholangiocarcinoma (ICC) is thought to arise from the intrahepatic biliary epithelia lining the epithelium and peribiliary glands [1] . ICC accounts for only 10-15% of all primary liver malignant cancers. However, epidemiological data have revealed a rapid increase in the incidence and mortality of ICC in recent years [2] . Unfortunately, ICC is a malignant disease with insidious onset, fast and invasive growth, a high recurrence rate and high mortality [3] [4] [5] . In a large cohort, patients with ICC suffered from postoperative recurrence and had a poor response to systemic chemotherapeutic treatments, with a five-year survival rate less than 5% [6] . The exploration of effective chemotherapies and molecularly targeted therapies is hindered by a poor understanding of ICC. Carbohydrate antigen 19-9 (CA19-9) is generally considered to be a promising predictor for ICC prognosis [7] ; however, some CA19-9-negative patients with ICC show rapid disease progression. Hence, novel prognostic markers for ICC treatment are urgently needed.
Farnesoid X receptor (FXR), a ligand-activated transcription factor encoded by the Nr1h4 gene, belongs to the nuclear receptor super family, is expressed in diverse tissues, such as the kidney, stomach, duodenum, colon, and liver. FXR is activated by bile acids (BAs) and, once activated, it could stimulate transcription of genes involved in synthesis, transport and metabolism of BAs and cholesterol [8] [9] [10] [11] [12] . Previously, we found that FXR protects against fructose-induced liver steatosis via inflammatory inhibition and adipose differentiationrelated protein (ADRP) reduction [13] . We also found that FXR is associated with β-catenin and inhibits its activity in hepatocellular carcinoma (HCC), which indicated that FXR provides protection against hepatocarcinogenesis [14] .
ICC and HCC share similar mechanism including common molecular subtypes and driver genes. Apart from its role in HCC development, evidence has begun to accumulate that FXR could be involved in ICC progression. FXR has been implicated in maintaining sterility of the biliary tract through various mechanisms, such as assisting vasoactive intestinal peptide receptor-1-induced choleresis [15] , promoting the expression of α-crystalline (a molecule that prevents oxidative stress), and combining with the activated vitamin D receptor (VDR) to induce the expression of the antimicrobial peptide, cathelicidin, in biliary epithelial cells [16] . FXR also participates in the metabolism of lipids and glucose [17] [18] [19] [20] , which is related to obesity, one of the risk factors of ICC [21, 22] . However, the clinical significance and functional role of FXR in ICC still remains elusive.
In the present study, we aimed to investigate the expression and clinical significance of FXR in ICC. We found that FXR was significantly downregulated in ICC and loss of FXR correlated with poor prognosis of patients with ICC. In addition, FXR acted as a powerful marker of prognosis in CA19-9 negative patients. FXR expression was negatively correlated with the IL-6 level in patients with ICC. FXR activation inhibited ICC growth and metastasis via IL-6 suppresssion in vitro and in vivo.
Materials and Methods
Human ICC Samples
Human liver tumor tissues were obtained from surgically resected specimens from patients with ICC at Zhongshan Hospital, Fudan University (Shanghai, P.R. China). Archived paraffin-embedded tumor tissues collected from 322 patients with ICC treated between 2005 and 2011 were used for tissue microarray construction and immunohistochemistry. Overall survival (OS) and time to recurrence (TTR) were defined as a time frame from the date of surgery to death and recurrence, respectively. If recurrence had not
Enzyme-linked immunosorbent assay (ELISA)
Tumor tissues from all patients with ICC were washed three times in cooled physiological saline to remove the blood and then dried with filter paper, weighed, 0.5 g was homogenized with 5 mL of physiological saline. After centrifugation, the supernatant was retained. IL-6 levels in the supernatants were detected using an ELISA kit according to the manufacturer's instructions (R&D, Minneapolis, USA). The cell supernatants of the ICC lines were centrifuged before testing.
Flow cytometry
The expression level of IL-6 was detected by flow cytometry according to the manufacturer's instructions (BD Biosciences, San Jose, CA, USA). Data was acquired with Diva (BD Biosciences, San Jose, CA, USA) and analyzed using FlowJo software (TreeStar).
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blotting
qRT-PCR was performed to assess mRNA expression on an ABI Prism 7500 Sequence Detection system according to the manufacturer's protocol. FXR forward primer: 5'-TCCGGACATTCAACCATCAC-3', reverse primer: 5'-TCACTGCACATCCCAGATCTC-3'. β-actin forward primer: 5'-GCACCACACCTTCTACAATG-3', reverse primer: 5'-TGCTTGCTGATCCACATCTG -3'. Total protein lysates extracted from cells and in order to explore the translocate of β-catenin, nuclear protein was extracted using a nuclear protein extraction kit (Pierce, USA). The protein was quantitated using a BCA Protein Assay Kit (Pierce, USA), then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto polyvinylidene difluoride membranes, and incubated with the corresponding antibodies. The experiments were repeated independently three times.
Cell functional experiments
A Cell Counting Kit-8 (Dojindo, shanghai, China) was used to detect the cell proliferation ability according to the manufacturer's specifications, as previous described [24] . Wound healing assays were performed as previously described [29] , all the cells were cultured with 1% FBS in RPMI 1640 culture media. The width of the wound was measured under the microscope at 0 h and 48 h after wounding to estimate the migratory ability of the ICC cells. Then we repeated the wound healing essay using mitomycin C (10μg/mL for 2 hours) to block the proliferation of ICC cells. The effect of FXR and IL-6 on cell invasion and migration were assessed using transwell assays, as described previously [28] . Each assay was repeated at least three times.
In vivo assays for tumor growth and metastasis RBE cells were chosen for tumor implantation because of its highly tumorigenicity in vivo [29, 30] compared with HuCCT1 and CCLP1. To make it easier to track the lung metastatic nodes, we used RBE-RFP cells. Cells (5 × 10 6 ) were suspended in 100 μL of serum-free RPMI 1640 and Matrigel (BD Biosciences, San Jose, CA, USA; 1:1) and injected subcutaneously into the upper left flank region of NOD-SCID mice. The mice were observed over 5 weeks for tumor formation. The tumor volume was measured twice weekly using a caliper and calculated as follows: V (cm 3 ) = ab 2 /2 [ a and b represented the largest and smallest tumor diameters measured at necropsy]. One week after inoculation, we fed one group of NOD-SCID mice with 10 mg/kg/day OCA; the control group was fed with vehicle solution. Upon sacrifice, the tumors were recovered and the volume of each tumor was determined. Part of the tumor tissue was taken for IL-6 testing. The lungs were removed and embedded in paraffin, and the total number of lung metastases was counted under the microscope, as described previously [31] .
Statistical analyses
Statistical analyses were carried out using SPSS software 20.0 (IBM SPSS, New York, NY, USA). The chisquare test was used to analyze the categorical data. The Kaplan-Meier method was performed to estimate the survival rate and the Cox proportional hazards regression model for multivariate survival analysis was used to evaluate the predictable value of recurrence and the survival rate. Correlation analysis was used to test the correlation between IL-6 and FXR. Student's t test was used to analyze comparisons between groups. A P value of < 0.05 (two-tailed) was considered statistically significant, and a P value of < 0.01 (twotailed) was considered very significant.
Cellular Physiology and Biochemistry
Results
FXR is downregulated in ICC and correlates with tumor size and metastasis
We performed IHC analysis to determine the expression and location of FXR in tumor tissues and matched non-tumor liver tissues from 332 patients with ICC. FXR positive signals were mainly localized in the nucleus (Fig. 1a) . The staining intensity of FXR in tumors was much lower than that in intrahepatic small bile duct cells, which have almost the same expression level of FXR as hepatocytes (Fig. 1a-c) . IHC staining using TMAs of 322 patients with ICC indicated that FXR expression was scored as negative or weak in most tumor tissues (176 of 322: negative, n=122; weak, n=54), while moderate or strong in most corresponding non-tumor liver tissues (222 of 322: moderate, n=103; strong, n=119) (Fig. 1c) .
Loss of FXR correlates with aggressive clinicopathological characteristics in patients with ICC
We further investigated the correlation between FXR expression and the clinicopathological features of patients with ICC. Based on the IHC results, all 322 patients with ICC were dichotomized as FXR low (n = 176) and FXR high (n = 146). Clinicopathologic analysis showed that loss of FXR was significantly correlated with tumor size (P < 0.001), lymph node metastasis (P = 0.007), vascular invasion (P = 0.016), tumor number (P = 0.036), tumor differentiation (P = 0.003), and TNM stage (P < 0.001) ( Table 1) .
Loss of FXR correlates with poor prognosis in ICC patients
We further investigated the prognositic value of FXR in this cohort of 322 patients. Kaplan-Meier curves analysis showed that patients in the FXR low group had significantly shorter TTR (time to recurrence) (median TTR 34.54 and 60.48 months, respectively; difference = 25.94 months; P < 0.001) and worse OS (overall survival) (median OS 35.84 and 67.41 months, respectively; difference = 31.57 months; P < 0.001) (Fig. 1d ) compared with those in the FXR high group. Univariate analysis also indicated that loss of FXR was associated with worse TTR (hazard ratio [HR] = 0.508, 95% CI 0.380-0.679, P < 0.001) and poor OS (HR = 0.503, 95% CI 0.376-0.672, P < 0.001) ( Table 2 and Table 3 ). Therefore, FXR expression in the tumor tissue could be considered as a relatively independent factor in the predicting prognosis of ICC patients.
FXR has prognostic value in CA19-9-negative patients with ICC
Several clinical studies demonstrated that the preoperative serum CA19-9 level is a promising predictor for ICC prognosis [7, 32, 33] . A low CA19-9 level is generally associated with favorable prognosis. Nevertheless, some patients with negative CA19-9 developed rapidly. Unfortunately, there is no reliable biomarker to differentiate the prognosis of CA19-9-negative patients. We hence tested the prognostic value of FXR in CA19-9-negative patients (cut-off point 37 U/mL). Among the 322 patients with ICC, 50.06% (163/322) patients had a negative CA19-9 serum level (< 37 U/mL). In these CA19-9-negative patients, we found that patients with negative FXR had an obviously worse TTR (TTR: 37.00 ± 5.20 months, P < 0.001) and OS (OS: 43.91 ± 4.43 months, P < 0.001) compared with patients with positive FXR (TTR: 66.48 ± 6.24 months, OS: 75.56 ± 5.74 months) (Fig. 2a ) In CA19-9-positive patients, we found that patients whose CA19-9 > 200 ng/mL had significantly worse prognosis, including shorter TTR (P<0.001) and OS (P<0.001), than patients whose CA19-9 < 200 ng/mL (Fig. 2b) , which was consistent with previous report [34] .
FXR inhibits IL-6 production in ICC cell lines
We detected the expression of FXR by western blotting and qPCR in four ICC cell lines, as well as a normal biliary epithelial cell line HIBEpic. Loss of FXR was observed in most ICC cell lines except RBE cells ( Fig. 3a and b) . Previous studies have shown that IL-6 is a critical pathogenic factor for ICC [35] . Thus, we explored whether FXR could regulate the expression of IL-6 in ICC cell lines. HuCCT1, which has a relative low level of endogenous FXR, was stimulated with the FXR agonist OCA, whose treatment for patients with primary cholestasis has entered clinical trials [36] . RBE and CCLP1 cells, with a relatively high level of endogenous FXR, were infected with FXR-shRNA lentivirus. FXR activation and knockdown efficiencies were confirmed using western blotting (Fig. 3a-d) . The results showed that IL-6 decreased when FXR was activated in HuCCT1 cells, while it increased when FXR was knocked down in CCLP1 and RBE cells ( Fig. 3e and f) . We also got the similar result in normal biliary epithelial cells HIBEpic (Fig.3c, d , e and f).
Loss of FXR correlates with increased IL-6 levels in patients with ICC
Among the autocrine cytokines generated in the inflammatory tumor microenvironment of HCC and ICC, IL-6 seems to be pivotal in the initiation and development of experimental HCC and ICC because of its contribution to advanced hepatocellular/biliary damage and proliferation of malignant cells [37] [38] [39] . To test the effect of FXR on IL-6 in vivo, we detected the IL-6 level in the tumor tissue of 97 patients with ICC randomly selected from 2015 February to 2016 August. We found that FXR expression was negatively correlated with the tumor IL-6 levels in the 97 patients (R 2 = 0.549, P < 0.001) (Fig. 3g) . 
FXR inhibits proliferation, migration, and invasion of ICC cells via IL-6 suppression
The clinical implications of FXR in ICC prompted us to explore its potential biological function. We first compared the proliferative ability in FXR-activated and FXR-silenced cells with their respective controls. The proliferation of FXR-activated HuCCT1 cells was significantly inhibited, while the proliferation of CCLP1-shFXR and RBE-shFXR cells was markedly enhanced, compared with their respective controls (Fig. 4a) . FXR-activated HuCCT1 cells showed decreased cell migration and invasion compared with control cells, as measured by transwell and wound healing assays (Fig. 4b and c) . In contrast, FXR-silenced cells showed increased cell migration and invasion compared with control cells (Fig. 4b  and c) . However, when we added IL-6 into the culture medium, the inhibitory effect of the FXR agonist OCA was rescued. Similarly, when IL-6 antibodies were added into the culture medium, the promotive effect of FXR-silencing was diminished in CCLP1 and RBE cells (Fig.  4. b and c) . In order to exclude the effect of proliferation on wound healing assay, we repeated this assay using mitomicin C (10 μg/mL for 2 hours) and obtained the similar results (Fig.  4d) . Taken together, FXR could inhibit the proliferation, migration, and invasion abilities of ICC cells, while IL-6 could rescue these effects in vitro.
FXR inhibits epithelial-mesenchymal transition (EMT) via IL-6 suppression
EMT is one of the most critical processes that provide cancer cells with increased migratory and invasive abilities [40] . Therefore, key molecules of EMT were evaluated in both FXRactivated and silenced ICC cells. Western blotting analysis indicated decreased epithelial markers, such as E-cadherin and ZO-1, and increased mesenchymal markers, such as N-cadherin, snail and Vimentin in FXR activated HuCCT1 cells compared with controls (Fig. 5a) . Conversely, increased E-cadherin and ZO-1, and decreased N-cadherin, snail and Vimentin were observed in FXR-silenced CCLP1 and RBE cells (Fig. 5b) . The nuclear accumulation of β-catenin, which translocates to the nucleus after EMT activation, was inhibited in FXR-activated ICC cells and promoted in FXR-silenced ICC cells (Fig. 5c and d) . In accordance with functional assays, IL-6 and IL-6 antibodies could rescue the inhibitory effect of FXR activation and promotive effect of FXR silencing on EMT, respectively (Fig. 5a-d) . Taken together, our results suggested that the FXR agonist OCA might inhibit EMT via IL-6 suppression in ICC cells. ) were infected with lentiviral shFXR-1, shFXR-2 and lentiviral shCtl vector in the presence and absence of IL-6 antibody. EMT-related proteins were examined by western blotting. β-actin was used as a control. c HuCCT1 cells were treated as indicated in Fig. 5a . The nuclear β-catenin level was examined by western blotting. Histone H3 was used as a control. d CCLP1 cells (left panel) and RBE cells (right panel) were treated as indicated in Fig.  5b . The nuclear β-catenin level was examined by western blotting. Histone H3 was used as a control. 
FXR inhibits ICC growth and metastasis in tumor xenograft models
We evaluated whether FXR plays a crucial role in the progression of ICC in a NOD-SCID mouse tumor xenograft model. RBE-RFP cells successfully formed tumors after orthotropic transplantation into NOD-SCID mice. The tumor size of the RBE-RFP cells-derived xenografts was 2.50 ± 0.63 cm 3 , which was significantly larger than that of tumors formed in NOD-SCID mice that were fed with OCA (1.15 ± 0.63 cm 3 ; P < 0.01) (Fig. 6a and b) . Similarly, the tumor weight of RBE-RFP cells-derived xenografts was 34 ± 2.8 mg, which was significantly larger than that of tumors formed in NOD-SCID mice fed with OCA (7.8 ± 1.30 mg; P < 0.001) (Fig.  6a and c) . Pulmonary metastasis occurred in 80% (4/5) of the RBE-RFP-derived xenografts, which was a higher rate than that observed in the NOD-SCID mice fed with OCA (20%, 1/5) (Fig. 6d, e and f) . The number of metastatic nodules of each grade in the lung was also greater in the control RBE-RFP group (Fig. 6d, e and g ). These results suggested that OCA, an FXR agonist, could inhibit tumor growth and lung metastasis in tumor xenograft models.
We next investigated the tumor tissue IL-6 level from NOD-SCID mice. Mice that were fed with OCA had a much lower IL-6 level compared with the control group (197.84 ± 43.15 pg/g vs. 78.95 ± 23.19 pg/g, P < 0.01) (Fig. 6h) .
Discussion
ICC, a highly fatal tumor, is the most frequent primary malignant liver tumor next to HCC. The prognosis of ICC remains extremely poor because of the special anatomical location and physiological activity of ICC. Compared with HCC, little is known about the molecular mechanism of the pathogenesis of ICC. New prognostic indices for ICC are urgently needed because of the limitation of CA199 in ICC patients. In the present study, we demonstrated the prognostic value of FXR expression in ICC. Importantly, we showed that FXR had prognostic value in CA19-9 negative patients with ICC. Moreover, loss of FXR changed the IL-6 level in patients with ICC.
FXR plays a vital role in maintaining the balance of BAs metabolism in the liver. In the normal physiological state, once BAs increase, FXR is strongly activated, promoting the excretion of BAs and reducing their reabsorption; thus, the concentration of BAs is reduced in the bile duct, which avoids excessive BAs damage to the liver bile duct cells. In patients with ICC, the secretion and reabsorption of BAs are switched into an aberrant state because of abnormal tumor metabolism. A large number of BAs accumulate in the bile ducts in patients with ICC, while according to our results, FXR expression decreased in the bile ducts. These effects led to excessive toxic BAs accumulation, along with damage to bile duct epithelial cells. The consequent inflammatory response could result in malignant transformation and stimulation of cholangiocarcinoma growth [41] .
Increasing evidence had demonstrated a close relationship between FXR and cholangiocarcinoma. Mice deficient for FXR spontaneously developed hepatobiliary malignancies [42, 43] . Martinez-Becerra et al [44] . and Dai et al [27] . previously showed downregulation of FXR mRNA and protein in ICC patients, respectively. However, the sample size was quite limited (12 patients with ICC in Martinez-Becerra's research and 26 patients with ICC in Dai's research). Our results complemented and reinforced the above conclusion, added new finding in this field. We demonstrated a significant loss of FXR in ICC tissues and a close correlation of reduced FXR expression in tumor tissues with increased IL-6 level, poor survival and high recurrence rates in patients with ICC. These results emphasized the potential prognostic value of FXR in ICC.
Compared with HCC, patients with ICC have a relative worse prognosis. Generally, CA19-9-negative patients with ICC have a relatively favorable prognosis. However, some CA19-9-negative patients with ICC progress rapidly, with poor prognosis. To date, a satisfactory prognostic factor for CA19-9-negative patients with ICC has not been discovered. In the present study, when applied to preoperative serum CA19-9-negative patients, FXR positive status could effectively differentiate patients with poor prognosis. Thus, to some extent, FXR expression could be a powerful tool to make rational treatment decisions in CA19-9 negative patients.
A recent study demonstrated that IL-6 has an integral role in ICC prognosis as a growth and survival factor of cholangiocarcinoma cells [45] . IL-6 and its receptor cannot be detected in the serum of healthy people, but can be detected in 100% of patients with bile duct cancer, in 92.9% of those with HCC, in 53.8% of those with liver metastatic colorectal cancer, and in 40% of those with benign biliary tract disease [31] . In the present study, we observed that FXR expression was negatively correlated with tumor IL-6 levels in patients with ICC. In line with our results, Xu et al [46] . reported that FXR activation could attenuate liver inflammatory damage by suppressing inflammation mediators such as IL-6 in an animal model of lipopolysaccharide-induced liver injury. Vavassori et al [47] . reported that FXR activation decreased the severity of inflammation by reducing proinflammatory cytokines, including IL-6, in animal models of colitis. Yang et al [48] . reported that FXR-deficient mice could spontaneously develop hepatobiliary malignancies with increased IL-6 levels. Maran et al [49] . reported that FXR deficiency promoted IL-6-mediated inflammation and tumorigenesis in chemical carcinogen-induced mice intestinal cancer. These important observations in animal models, combined with our findings on human subjects, implied that FXR regulates autocrine-paracrine communication among ICC cells by IL-6 inhibition. Previous studies revealed that NF-κB activated IL-6 transcription through a consensus NF-κB binding site [50] . While FXR has been reported to antagonize NF-κB in hepatic inflammatory response [51] . We hence proposed that FXR might suppress the expression of IL-6 by NF-κB inhibition. However, the detailed mechanism still need further investigation.
EMT, which refers to the pathway of the transformation of epithelial cells to mesenchymal cells, plays a critical role in embryonic development, chronic inflammation, tissue remodeling, cancer metastasis, and a variety of fibrotic diseases. Previous reports showed that IL-6 could induce EMT in breast cancer, pancreatic cancer, and lung cancer [52] [53] [54] . In the present study, we verified that IL-6 is an autocrine factor that promotes EMT of ICC cells. At the same time, its expression was inhibited by OCA, which is an FXR agonist used for the oral treatment of cholestatic liver diseases, including primary billiary cirrhosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis [55, 56] . These results suggested that OCA might be a useful tool for treating patients with ICC. 
Conclusion
In summary, this study indicated that loss of FXR plays a pivotal role in tumorigenesis of ICC patients and acted as a prognostic marker, especially in CA19-9-negative patients with ICC. The FXR agonist OCA might represent a novel drug to treat ICC. 
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